Is healthspan the same as life expectancy?

No. Life expectancy quantifies the total years lived. Healthspan refers to the years spent in largely good health; it is approximated using measures such as health-adjusted life expectancy (HALE), from which years lived with illness or disability are subtracted. The difference between the two is the healthspan gap.

Do peptides demonstrably extend healthspan?

This has not been established so far. Findings on substances such as MOTS-c or Epitalon come predominantly from cell and animal models or from small investigations. Large, controlled human studies are largely lacking, and such peptides are not approved as longevity medicines in the EU and the USA. Corresponding claims are to be classified as an assertion.

Will the gap between healthy and lived years close on its own?

The global data point rather in the other direction: the healthspan-lifespan gap grew between 2000 and 2019, driven above all by chronic diseases. The compression of morbidity that researchers hoped for has so far not occurred across the board at the population level.

Longevity Basics7 min readLast reviewed: June 2026

Lifespan vs. Healthspan: Why Longevity Means More Than Just "Living Longer"

One pair of terms keeps coming up in the longevity debate: lifespan and healthspan. The lifespan is the number of years lived; the healthspan refers to the years spent in largely good health - that is, without significant chronic illness or disability. The crucial point: the two do not move in lockstep. Worldwide, life expectancy has risen more sharply in recent decades than the number of healthy years, so that a measurable gap has emerged. This article explains the terms factually, puts the actual evidence into context, and makes transparent what is well established - and what so far remains primarily hope and hypothesis.

Machine-assisted translation. The German original is the authoritative version.

Key points

Lifespan (years lived) and healthspan (healthy years) do not grow in lockstep - between them lies a measurable gap.
The "compression of morbidity" (Fries, 1980) is the core idea of longevity: shortening the ill phase at the end of life, not just extending life.
Real-world data show the opposite of compression: the global healthspan gap stood at around 9.6 years in 2019 and has grown since 2000 (USA: ~12.4 years).
For marketed "longevity peptides" such as MOTS-c or Epitalon, large controlled human studies are lacking; they are not approved anti-aging remedies.
The pair of terms is a useful framework for thinking that helps to scrutinize longevity promises critically - it does not replace medical advice.

What healthspan means - and how it differs from lifespan

Lifespan is easy to measure: it ends with death. Healthspan is more complex, because "healthy" has to be defined. Research often uses health-adjusted life expectancy (HALE) for this purpose - that is, the expected number of years in full health, with years lived with illness or disability subtracted proportionally.

The difference between the two figures is called the healthspan-lifespan gap: the years at the end of life that are typically marked by illness. It is precisely this gap that serves as the actual point of reference for many longevity debates. The stated goal is usually not first and foremost to raise the maximum age, but to increase the number of healthy, functional years and to keep the ill phase at the end of life as short as possible.

Lifespan: total years lived (measure: life expectancy).
Healthspan: years in largely good health (measure: HALE, among others).
Healthspan gap: the mostly ill years at the end of life.
"Living longer" and "ageing more healthily" are not the same thing.

Compression of morbidity: the central idea behind it

The concept that underpins healthspan thinking is the "compression of morbidity." It goes back to the Stanford physician James F. Fries, who coined it in 1980 in the New England Journal of Medicine. The hypothesis: if the onset of chronic illness can be pushed back further - and faster than life expectancy rises - then the ill phase at the end of life shrinks. Illness would, as it were, be "compressed" into a shorter window.

The opposite picture is the "expansion of morbidity": people do live longer, but spend the additional years predominantly ill, so that the ill phase lengthens. Which scenario occurs depends on whether healthspan or lifespan grows faster. This is precisely where the scientific and public-health interest in longevity comes in - it is about the quality of the years gained, not just their number.

Compression of morbidity: illness begins later and lasts a shorter time (Fries, 1980).
Expansion of morbidity: a longer life, but more ill years.
Which scenario applies depends on the pace of both curves.

What the data really show

This is where it gets concrete - and sobering. An analysis by Garmany and Terzic of 183 WHO member states, published in JAMA Network Open in 2024, determined a global healthspan-lifespan gap averaging around 9.6 years for 2019. This gap has not shrunk but grown: from about 8.5 years in 2000, an increase of roughly 13 percent. The largest gap was found in the USA, at around 12.4 years. Women on average had a larger gap than men.

A follow-up analysis by the same group (Communications Medicine, 2025) showed that while the gap exists everywhere, it varies markedly by region in its extent and in the diseases that cause it. A key driver is non-communicable, chronic diseases. The message of the data is therefore: in the real world, healthspan has so far not improved fast enough on average to keep pace with lifespan - the compression Fries hoped for has not yet occurred at the population level worldwide. It is also important to note: these figures describe populations via statistical measures such as HALE. They say nothing about the effect of individual substances and are not based on intervention studies of specific compounds.

Global gap 2019: ~9.6 years, grown from ~8.5 years (2000).
USA: ~12.4 years - the largest gap in the analysis.
Main driver: chronic, non-communicable diseases.
The data are population statistics, not evidence for individual remedies.

From concept to compound: human vs. animal data and regulatory status

From the healthspan idea, geroscience derives the notion of addressing the ageing processes themselves, rather than only treating individual diseases (as discussed, for example, in a perspective in npj Regenerative Medicine, 2021). In forums and marketing, this concept is readily transferred to certain peptides - such as MOTS-c (a mitochondrially encoded peptide) or Epitalon (a synthetic tetrapeptide). Here, sobriety is in order.

For such substances, the frequently cited "anti-aging" findings come predominantly from cell and animal models or from small, methodologically limited investigations. Robust, large, controlled human studies on an extension of healthspan are largely lacking. From a regulatory standpoint, these peptides are not approved as longevity medicines in the EU and the USA; they are considered investigational or research substances with no recognized anti-aging benefit. Claims that a particular peptide "extends healthspan" are therefore to be classified as an assertion, not as an established fact. Anyone who wishes to make health decisions should seek medical advice.

Geroscience targets ageing processes rather than individual diseases.
MOTS-c, Epitalon and others: evidence predominantly from cell/animal models.
Large, controlled human studies on healthspan are largely lacking.
No longevity approval status in the EU/USA - investigational/research substances.
"Extends healthspan" is an assertion here, not evidence.

Putting the hype in perspective

The terms lifespan and healthspan are serious and well anchored in science - the healthspan gap is a genuinely measured phenomenon. The hype begins where a sensible goal ("more healthy years") turns into a concrete promise made by individual products. The fact that healthspan is a worthwhile goal for society does not mean that a particular supplement, peptide, or protocol demonstrably extends it.

The distinction is useful as a framework for thinking: it helps to scrutinize longevity offerings critically. The honest question is not "Does it make me older?" but "Is there robust human data that it adds healthy years - and what is the regulatory status?". At the population level, the best-evidenced levers for healthy years so far point toward fundamentals such as physical activity, nutrition, sleep, not smoking, and the management of chronic diseases - not toward individual miracle remedies.

The concept is serious; individual promises of salvation often are not.
Test question: robust human data + honest approval status?
Well-evidenced healthspan levers so far are above all lifestyle and disease management.

Related substance profiles

MOTS-c

A mitochondrially encoded peptide — an "exercise mimetic" of research, not approved.

Epitalon (Epithalon)

Synthetic tetrapeptide — research substance for aging, not approved.

Frequently asked questions

Is healthspan the same as life expectancy?: No. Life expectancy quantifies the total years lived. Healthspan refers to the years spent in largely good health; it is approximated using measures such as health-adjusted life expectancy (HALE), from which years lived with illness or disability are subtracted. The difference between the two is the healthspan gap.
Do peptides demonstrably extend healthspan?: This has not been established so far. Findings on substances such as MOTS-c or Epitalon come predominantly from cell and animal models or from small investigations. Large, controlled human studies are largely lacking, and such peptides are not approved as longevity medicines in the EU and the USA. Corresponding claims are to be classified as an assertion.
Will the gap between healthy and lived years close on its own?: The global data point rather in the other direction: the healthspan-lifespan gap grew between 2000 and 2019, driven above all by chronic diseases. The compression of morbidity that researchers hoped for has so far not occurred across the board at the population level.

Sources

This article is for information and education only. It does not replace medical advice and deliberately contains no dosing, usage or sourcing information.

← All guide articles